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Abstract
Objectives. The S100A4 protein is known as a metastasis promoting factor; however, its involvement in
non-malignant diseases such as RA and psoriasis has been recently described. The aim of this study was
to investigate the expression and possible role of S100A4 in idiopathic inflammatory myopathies.
Methods. S100A4 protein expression was detected by immunohistochemistry in muscle tissue from con-
trol individuals (n= 11) and patients with PM and DM (n= 8/6). IF staining was used to co-localize S100A4
with selected cells. Cytokine expression and protein synthesis in S100A4-treated cells were analysed by
RT-PCR and ELISA.
Results. S100A4 protein was significantly up-regulated in muscle tissue of patients with inflammatory
myopathies compared with control individuals and was associated particularly with the presence of mono-
nuclear infiltrates. Only few regenerating muscle fibres in PM/DM expressed S100A4. Then we analysed
the effect of S100A4 on human myocytes and peripheral blood mononuclear cells (PBMCs). Although
S100A4 did not affect myocytes, stimulation of PBMCs with S100A4 significantly induced the expression
and synthesis of TNF-a, IL-1b and IL-6, but not of IFN-a. We showed that S100A4 is not directly involved
in perforin/granzyme B-induced apoptosis and that it does not modulate the expression of Bax and Bcl2
mRNA in myocytes and PBMCs.
Conclusion. Increased expression of S100A4 in inflamed muscle tissue highlights its potential role in the
pathogenesis of inflammatory myopathies. S100A4 may act as a cytokine-like factor indirectly promoting
muscle fibre damage by stimulating mononuclear cells to increase the synthesis of pro-inflammatory
cytokines.
Key words: S100A4, Polymyositis, Dermatomyositis, Peripheral blood mononuclear cells, Myocytes,
Inflammation.
Introduction
PM and DM are chronic inflammatory autoimmune myo-
pathies of unknown aetiopathogenesis that are clinically
characterized by symmetric proximal skeletal muscle
weakness [1]. The main pathognomonic feature of
PM/DM is the mononuclear inflammatory cell infiltration
associated with muscle fibre necrosis and regeneration.
In patients with PM, inflammatory cells often surround and
invade non-necrotic muscle fibres and primarily include
CD8+ T cells and macrophages, whereas in patients with
DM, CD4+ T cells, macrophages and dendritic cells pre-
dominate mostly in perivascular areas. In addition, com-
pared with healthy muscles, affected muscle fibres
express both MHC Class I and II antigens and may them-
selves be the site of autosensitization [2]. In chronic myo-
sitis, macrophages phagocytose the necrotic muscle
fibres and muscles can then be replaced by fibrous con-
nective tissue. Taken all together, T cells, macrophages,
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immunoglobulins and muscle fibres appear to be critical
components for final damage of the muscles. There is
evidence that not only inflammatory mononuclear cells
within the muscle tissue, but also endothelial cells and
muscle fibres themselves produce a number of
pro-inflammatory mediators contributing to the pathogen-
esis of PM/DM [3, 4]. Increased expression of IL-1b, IL-6,
TNF-a or IFN-a has been demonstrated in muscle tissue
of myositis patients [3, 4].
S100A4, also known as metastasin (Mts1), was
described several years ago as metastasis-specific pro-
tein and subsequently has been demonstrated as a me-
diator of tumour progression and metastasis [5, 6]. In
recent years, it has become apparent that S100A4 also
participates in pathogenesis of non-malignant human dis-
orders [7]. We have reported increased amounts of
S100A4 protein in blood, SF and synovial tissue of pa-
tients with RA [8, 9]. The level of S100A4 in plasma cor-
relates with disease activity of patients with RA [10]. In
addition, it has been demonstrated that S100A4 regulates
apoptosis and expression of several matrix degrading en-
zymes in RA synovial fibroblasts [8, 9] as well as expres-
sion of TNF-a in monocytes [10]. S100A4 is up-regulated
in the upper dermis of psoriatic skin and the protein was
shown to be actively involved in the pathogenesis of psor-
iasis [11]. Association of S100A4 protein with autoimmune
inflammatory diseases and with some fibrotic processes
has recently been suggested [12, 13]. In the present
study, we investigated the expression and local distribu-
tion of S100A4 in muscle tissue of patients with idiopathic
inflammatory myopathies and studied the role of S100A4
in the pathogenesis of inflammation and muscle tissue
damage.
Materials and methods
Immunohistochemical studies
Muscle tissue samples were obtained under local anaes-
thesia using the open biopsy technique from vastus later-
alis (or medialis) muscle. Muscle tissue biopsies were
obtained from patients with PM (n= 8) and DM (n= 6)
during diagnostic muscle biopsy from a biopsy site se-
lected using MRI [14]. Patient clinical and demographic
data at the time of muscle biopsy are given in Table 1.
Patients with PM/DM fulfilled Bohan and Peter diagnostic
criteria [15, 16]. Control non-inflammatory muscle tissue
was obtained from individuals with myasthenia gravis
(n= 5) and from individuals (n= 6) who underwent diagnos-
tic muscle biopsy, but did not fulfil diagnostic criteria for
PM or DM. The study was approved by the local ethics
committee (RNDr. Ivana Pu˚tova´) and each patient signed
an informed consent before biopsy.
Serial cryostat sections of muscle tissue were fixed in
acetone and 4% paraformaldehyde and blocked in 0.3%
H2O2. Sections were washed in Tris-buffered saline (TBS)
and incubated with polyclonal rabbit anti-S100A4 antibo-
dies 1 : 5000 [produced at the Danish Cancer society
(DCS), Denmark] for 1 h, and rinsed again in TBS buffer.
Antigenantibody complexes were visualized by the
Histofine detection system (Nichirei Biosciences Inc.)
using 3, 30-diaminobenzidine as chromogene. Sections
were counterstained with Harris’s haematoxylin. Isotype-
specific antibodies were used as negative controls. The
intensity of S100A4 expression was scored using a
semi-quantitative four-point scale: 0, represented no
staining, while a score of 13 represented weak, moderate
and strong staining intensity, respectively. The intensity of
S100A4 staining was assessed by two pathologists skilled
in reading muscle biopsies and mean scores were calcu-
lated for statistical analysis. In the case of weak or bor-
derline staining intensity any inter-observer discrepancies
were resolved by secondary evaluation until agreement
was reached.
For double-labelling experiments we used the same
sections. Cryostat muscle sections were fixed in acetone,
rinsed in TBS and blocked in TBS supplemented with 5%
goat serum. Primary antibodies were incubated overnight
in a cold room: polyclonal and monoclonal anti-S100A4
diluted 1 : 2000 (produced in the Department of Molecular
Cancer Biology, DCS); monoclonal anti-CD68 (diluted
1 : 200; Dako); anti-CD1a (diluted 1 : 200; Dako);
anti-CD3 (diluted 1 : 400; Abcam); anti-vimentin (diluted
1 : 4000; Neo Markers); anti-CD20cy (diluted 1 : 100;
Dako); anti-alpha smooth muscle actin (diluted 1 : 4000;
Sigma); mast cell tryptase (diluted 1 : 1000); von
Willebrand factor (diluted 1 : 500; Dako). Secondary anti-
bodies coupled to Alexa 488 or Alexa 568 were used
at a dilution of 1 : 2000 (Molecular Probes, Leiden, The
Netherlands). Samples were analysed by confocal micros-
copy using an LSM 510 microscope (Carl Zeiss
MicroImaging, Oberkochen, Germany).
Isolation of peripheral blood mononuclear cells,
myocyte culture and stimulation
Human peripheral blood mononuclear cells (PBMCs) were
isolated from peripheral blood of patients with idiopathic
TABLE 1 Patient characteristics at the time of muscle
biopsy
Patient Age (years) Sex Diagnosis
Treatment at the
time of biopsy
1 71 F PM Pred 40
2 63 M PM Pred 60
3 56 F PM None
4 49 M PM None
5 54 M PM None
6 50 F PM None
7 57 F PM None
8 78 F PM None
9 56 F DM/Scl Pred 60
10 64 F DM None
11 30 M DM None
12 74 F DM None
13 74 F DM Pred 60
14 61 F DM Pred 20, MTX
F: female; M: male; Scl: scleroderma; Pred: prednisolone.
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inflammatory myopathies (n= 510) by FicollPlaque
density gradient centrifugation. PBMCs were seeded at
5.0105 cells (confluent cells condition) per 1 ml of
advanced RPMI medium 1640 (Invitrogen, Carlsbad, CA,
USA) in 35-mm diameter culture plates. Commercially
available human skeletal muscle cells (Lonza, Basel,
Switzerland) were cultivated in DMEM (Invitrogen)
supplemented with 10% fetal calf serum at 37C with
5% CO2. Cells were seeded at 1.0 105 cells per well in
6-well culture plates in 1 ml of DMEM without serum. The
cells were treated with a S100A4 multimer (1 mg/ml) and
lipopolysaccharide (100 mM) for 6 and 24 h at 37C with
5% CO2. The doses of S100A4 and time courses were
given according to our previous experiments [8, 9]. The
active S100A4 multimer was obtained from recombinant
His6-tagged protein by gel filtration as described previ-
ously [17]. After 6 h, cells were lysed by RNeasy lysis
buffer (Qiagen, Hombrechtikon, Switzerland), cell culture
supernatants were collected after 24 h of exposure to
S100A4 and stored at 80C.
RT-PCR analysis
Total RNA from myocytes and PBMCs was extracted
using the MagNa Pure Compact RNA isolation kit for
MagNA Pure Compact Instrument (Roche Diagnostics
GmbH, Germany). Complementary DNA was obtained
by reverse transcription using a high-capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). PCR was performed according to a stand-
ard protocol. Pre-developed primers (Applied Biosystems)
were used to detect IL-1b, IL-6, TNF-a, IFN-a, Bax and
Bcl-2 mRNAs. 18 S ribosomal RNA was used for correct-
ing the results with the comparative threshold cycle (Ct)
method for relative quantification, and the Ct of 18 S ribo-
somal RNA was subtracted from the Ct of studied genes,
giving the Ct values. The 7900HT Fast Real-time PCR
system was used to perform real-time PCR (Applied
Biosystems).
ELISA
Protein levels were measured in the cell culture super-
natants using ELISA kits according to the manufacturer’s
protocol: TNF-a, IL-1b, IL-6 (Ray Biotech, Inc., Norcross,
GA, USA), IFN-a (PBL InterferonSource, Piscataway, NJ,
USA), granzyme B and perforin (Abcam, Cambridge, UK).
The analyses were performed using ELISA reader
SUNRISE (Tecan, Salzburg, Austria) at a wavelength of
450 nm.
Statistical analyses
Differences in the expression of S100A4 between myositis
and control muscle samples were determined using the
median test and Pearson’s chi-square test. Changes in
mRNA expression and protein synthesis were performed
using the Student’s paired t-test. P-values were con-
sidered statistically significant when <0.05.
Results
Expression of S100A4 protein in muscle tissue of
inflammatory myopathies
S100A4 expression in muscle tissue was detected in all
patients with PM/DM and the staining intensity was sig-
nificantly enhanced compared with control muscle tissue
(Fig. 1). There was consistent expression of S100A4 within
the inflammatory infiltrates in the muscle tissue, although
its intensity varied from mild to very strong (Table 2).
Compared with control muscle tissue, S100A4 was
up-regulated in mononuclear cells within the inflammatory
infiltrates in the affected muscle tissues (Fig. 1),
particularly in those surrounding necrotic muscle fibres.
Moreover, few muscle fibres—mostly regenerating
muscle fibres (8/14) in PM/DM expressed S100A4
(supplementary figure 1, available as supplementary
data at Rheumatology Online), whereas this was not
seen in normal muscles. A similar pattern of S100A4
staining intensity was demonstrated in endothelial cells
of large perimysial vessels and endomysial capillaries
between control and PM/DM muscle tissues. The
S100A4 staining intensity was similar between PM and
DM muscle specimens.
Cell-specific co-localization of S100A4 protein in
muscle tissue
To determine cell-specific localization of S100A4 protein
in muscle tissue samples of patients with idiopathic
inflammatory myopathies, we performed double IF stain-
ing using antibodies against S100A4 and cell-specific
markers for various cell types. Except for B-lymphocytes
(CD20), S100A4 protein was ubiquitously expressed in
inflamed muscle tissue (Fig. 2). We demonstrated clear
co-localization of S100A4 with markers specific for T
lymphocytes (CD3), macrophages (CD68), dendritic cells
(CD1a), non-epithelial cells of mesenchymal origin, mostly
fibroblasts (vimentin), alpha-smooth muscle actin-positive
cells (myofibroblasts, pericytes and some others),
endothelial cells (von Willebrand factor) and mast cells
(mast cell tryptase). These data indicate that S100A4
expression patterns are comparable to those found in
our previous findings in RA and psoriasis [9, 11].
S100A4 enhances expression of pro-inflammatory
cytokines in mononuclear cells, but not in myocytes
Taking into consideration that S100A4 is up-regulated at
local sites of inflammation, we further investigated the role
of S100A4 in the process of inflammation. We demon-
strated that treatment of PBMCs with the S100A4 protein
significantly up-regulates the expression of IL-1b
(P< 0.001), IL-6 (P< 0.001) and TNF-a (P< 0.01), but not
IFN-a, mRNAs after 6 h compared with untreated cells
(Fig. 3A). Consistently with the mRNA expression profile,
production and release of IL-1b [9.972 (0.895) vs 1.084
(0.149) pg/ml; P< 0.005], IL-6 [42.960 (3.666) vs 3.973
(1.684) pg/ml; P< 0.005] and TNF-a [31.970 (5.054) vs
4.902 (1.754) pg/ml; P< 0.01], but not IFN-a [1.479
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(0.239) vs 1.620 (0.294) pg/ml; not significant], by PBMCs
was also significantly increased upon treatment with
S100A4 compared with untreated cells after 24 h
(Fig. 3B). To further define whether S100A4 participates
in the process of muscle tissue damage, we analysed
expression of apoptotic markers as well as release of
granzyme B and perforin from mononuclear cells treated
with S100A4. However, the expression of Bax and Bcl2 as
well as production of perforin and granzyme B was not
changed in PBMCs treated with S100A4 compared with
untreated cells (Fig. 3A). Furthermore, expression of IL-1,
IL-6 and TNF-a mRNAs remained unchanged in myocytes
treated with S100A4 compared with untreated cells (data
not shown). These findings suggest that the increased
presence of S100A4 in muscle tissue may enhance
production of several cytokines participating in the pro-
cess of inflammation in myositis.
Discussion
This is the first study demonstrating increased expression
of S100A4 protein in muscle tissue from patients with
idiopathic inflammatory myopathies compared with con-
trol individuals. Here, we show that the protein is particu-
larly associated with mononuclear infiltrates and may
play a role in the inflammation contributing to muscle
fibre damage. When incubated with mononuclear
cells, S100A4 promotes the production of several pro-
inflammatory cytokines participating in the pathogenesis
of inflammatory myopathies.
FIG. 1 Imunohistochemical staining for S100A4 protein in muscle tissues: (A1) PM, (B1) DM and (C1) control muscle
tissue. The S100A4 expression was particularly increased in mononuclear cells within the inflammatory infiltrates sur-
rounding necrotic muscle fibres. Several regenerating muscle fibres in an inflammatory myositis expressed S100A4,
whereas it was not present in a control muscle tissue. However, endothelial cells of large perimysial vessels and
endomysial capillaries were positive for S100A4 in all patients and controls. The S100A4 staining intensity was
comparable between PM and DM muscle specimens. Mouse immunoglobulin G was used as a control (A2, B2, C2).
Original magnification was 200.
TABLE 2 Expression of S100A4 related to different cellular compartments in muscle tissues from patients with PM/DM
and control individuals
Location PM/DM Controls Median test, P
Pearson’s chi-square
test, P
Mononuclear cell infiltrates 2 (13) 0 (00) 0.001 <0.0001
Vessels and capillaries 1.5 (13) 1.5 (12) 1.0 0.840
Interstitial connective tissue 1 (02) 1 (12) 0.661 0.301
Muscle fibres 0.5 (01) 0 (00) 0.003 0.010
The intensity of S100A4 expression was scored using a semi-quantitative four-point scale. Score 0 represented no staining;
1: weak; 2: moderate; and 3: strong staining intensity. The numbers represent median (minmax).
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Recent studies have shown that S100A4 can be asso-
ciated not only with cancer, but also with some inflam-
matory and fibrotic diseases (for review see [12, 13]).
We have previously demonstrated increased S100A4 ex-
pression in RA compared with OA synovial tissues with
the protein being abundantly produced by synovial fibro-
blasts, several immune cells and endothelial cells [8, 9].
Very similar patterns of S100A4 distribution were docu-
mented in the dermis of psoriatic skin, where S100A4
was also up-regulated [11]. The results in this study are
consistent with previous findings. We found increased ex-
pression of S100A4 in mononuclear cells particularly at
sites of inflammatory infiltrates surrounding necrotic
muscle fibres of patients with inflammatory myopathies.
These results are in agreement with the study of Seeliger
et al. [18] that described increased expression of other
S100 family calcium-binding proteins S100A8 and
S100A9 in inflamed muscle tissue of patients with inflam-
matory myopathies. S100A8/9 dimer was expressed
by activated macrophages, but did not appear to be
expressed in myotubes. In contrast, we have detected
S100A4 protein also in some regenerating muscle fibres.
Whereas S100A4 protein was not found in the normal
mature cardiac myocytes, it is present in myocytes
within the infarct border zones and a role for S100A4
FIG. 2 Cell-specific expression of the S100A4 protein in
muscle tissue using double IF staining. The cells
are labelled by cell-specific markers: anti-CD68
(macrophages); anti-CD20 (B-lymphocytes); anti-CD3
(T-lymphocytes); anti-CD1a (dendritic cells);
anti-smooth-muscle actin (myofibroblasts and pericytes);
vimentin (cells of mesenchymal origin); von Willebrand
factor (endothelial cells) and mast cell tryptase (mast
cells). The scanning dimensions are for all images:
0.22mm 0.22mm, except for CD20: 0.06 mm0.06mm,
CD1a: 0.11 mm0.11mm.
FIG. 3 S100A4 protein significantly increased the
expression (A) and release (B) of TNF-a, IL-1b and IL-6,
but not IFN-a, in PBMCs. Bax, Bcl2 mRNA (A), and
granzyme B and perforin proteins (B) were not changed in
PBMCs treated with S100A4 protein. Expression of mRNA
was determined after 6 h and protein levels in cell culture
supernatants were measured after 24 h. All the results are
expressed as mean and S.E.M., *P< 0.01; **P< 0.005;
+P< 0.001.
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protein as a factor eliciting hypertrophic response and
pro-survival activities has been suggested [19]. In this
context, one can hypothesize that S100A4 might be en-
gulfed by regenerating myofibres, thus counter-parting
mechanisms involved in the process of muscle fibre
injury in myositis. Endothelial cells of large perimysial ves-
sels and endomysial capillaries exert similar patterns of
S100A4 expression between control and inflamed
muscle tissue suggesting more general roles for S100A4
in human physiological and pathological functions.
There is clear evidence that S100A4 protein is increased
at sites of inflammation [811]. Recently, several pro-
inflammatory cytokines have been demonstrated to be
responsible for the increase in S100A4 production [20].
However, when released from the cells, S100A4 also
exerts cytokine-like activities and modulates the expres-
sion of several genes that are involved in the process of
tissue damage [612, 20, 21]. The functional activity of
extracellular S100A4 protein is attributed to the multimeric
forms of the protein [10, 17, 22]. Since we found increased
amounts of S100A4 protein in interstitial connective tissue
surrounding necrotic muscle fibres, we hypothesized that
the protein might be implicated in the observed muscle
fibre damage and examined the effects of extracellular
S100A4 on these cells. Mononuclear cell infiltrates, par-
ticularly cytotoxic T cells and NK cells, participate directly
in the process of muscle damage by releasing granzyme B
and perforin [23], which however, were not induced by the
treatment with S100A4. Although S100A4 protein did not
modulate the expression of pro-inflammatory cytokines or
apoptotic mediators in myocytes, it significantly increased
the expression and release of IL-1b, IL-6 and TNF-a from
mononuclear cells. The diversity of S100A4 effects can be
explained by the fact that mononuclear cells, but not myo-
cytes, express TLR-4 ([24], supplementary figure 2, avail-
able as supplementary data at Rheumatology Online),
which based on our unpublished observation, participate
in S100A4-induced cell activation. Thus, it could be
hypothesized that locally up-regulated S100A4 protein
participates in the muscle fibres damage indirectly, by
activation of mononuclear cells to synthesize pro-
inflammatory cytokines that have been shown to contrib-
ute to the pathogenesis of inflammatory myopathies
[3, 2327].
In summary, our study shows increased expression of
S100A4 protein in inflamed muscle tissue of patients with
inflammatory myopathies. The protein originates from
inflammatory and resident tissue cells and in an autocrine
and/or paracrine manner may increase the synthesis of
pro-inflammatory cytokines in mononuclear cells, and
thus indirectly participate as a factor contributing to the
pathogenesis of inflammatory myopathies.
Rheumatology key messages
. S100A4 protein is significantly up-regulated in in-
flammatory myopathies.
. S100A4 induces the production of pro-inflammatory
cytokines in mononuclear cells.
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